Physician profile
Olivia E Hubbard
NPI 1982282646
$3,920.69
in general payments reported to CMS, 2019-2025
31 companies · $694 in 2025
The $694 reported for 2025 was more than what 81% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $120 · 2023: $1,327 · 2024: $1,779 · 2025: $694.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,801.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,800.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $673.18 | 2024-2025 | Intellis Adaptivestim, Inceptiv, Synchromedii |
| Collegium Pharmaceutical, INC. | $618.01 | 2022-2025 | Belbuca, Xtampza, Nucynta |
| Spinal Simplicity, LLC | $441.69 | 2023-2025 | Ha Minuteman G3-R |
| Abbvie INC. | $364.30 | 2023-2025 | |
| Boston Scientific Corporation | $324.09 | 2024-2025 | General - Pain Management |
| Pfizer INC. | $256.24 | 2023-2024 | |
| Nalu Medical, INC. | $236.63 | 2023 | Nalu Neurostimulation System |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $158.64 | 2022-2025 | Relistor |
| Scilex Pharmaceuticals INC. | $105.39 | 2023-2024 | Ztlido |
| Abbott Laboratories | $83.60 | 2024 | Proclaim, Eterna |
| Si-Bone, INC. | $65.36 | 2025 | |
| Averitas Pharma INC. | $62.00 | 2023-2024 | Qutenza |
| Lundbeck LLC | $54.38 | 2024 | Vyepti |
| Biohaven Pharmaceutical Holding Company LTD. | $44.56 | 2022 | |
| Merz Pharmaceuticals, LLC | $39.95 | 2023 | Xeomin |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotronik Nro, INC. | $39.32 | 2024 | Prospera |
| Foundation Fusion Solutions, LLC | $37.34 | 2024 | |
| Ibsa Pharma INC. | $35.46 | 2023 | Tirosint, Licart |
| Relievant Medsystems, INC. | $33.93 | 2023 | Intracept |
| Protega Pharmaceutials INC | $33.87 | 2025 | Roxybond |
| Pacira Pharmaceuticals Incorporated | $22.57 | 2023 | Zilretta, Iovera |
| Spr Therapeutics, INC | $22.29 | 2024 | Sprint Pns System |
| Depuy Synthes Sales INC. | $21.97 | 2023 | Monovisc |
| Azurity Pharmaceuticals, INC. | $21.70 | 2024 | Horizant |
| Lilly USA, LLC | $21.62 | 2024 | Emgality |
| Bioventus LLC | $21.44 | 2023 | Durolane |
| Hologic Sales and Service, LLC | $19.01 | 2025 | Aptima |
| Hikma Pharmaceuticals USA | $16.75 | 2023 | Kloxxado |
| Teva Pharmaceuticals USA, INC. | $15.94 | 2024 | Ajovy |
| Ipsen Biopharmaceuticals, INC | $15.44 | 2022 | |
| Redhill Biopharma INC. | $14.02 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Olivia Hubbard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.